跳至主要内容
临床试验/NCT00161356
NCT00161356终止4 期

Blood, Bile and Tissue Pharmacokinetics of Single Dose Liposomal Amphotericin B (AmBisome ®) in Liver Transplant Patients.

The University of Texas Health Science Center, Houston2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2005年9月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
10
试验地点
2
主要终点
Tissue concentration of ambisome

研究概览

简要总结

In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body. This drug is approved for treatment of infections caused by fungus and is known to be effective against most of the fungal infections, which can happen after liver transplantation. By taking small pieces (less than quarter of a teaspoon) of liver and fat during the liver transplant operation, we can measure how much of the drug is concentrated in the liver. After that, we will measure the level of the drug in the blood and in the bile that comes out of a small tube which is inserted into the bile tube as a routine in all liver transplant patients. These measurements will be taken daily for a week and then weekly for another 3 weeks.

We are inviting you to take part in this study in order to increase our knowledge of the behavior of this drug so that we can find the most effective treatment to prevent fungal infections in liver transplant patients.

详细描述

Fungal infections continue to be a source of serious morbidity and mortality in liver transplant patients. Liposomal Amphotericin B (AmBisome ®) has been shown in animals to be concentrated in the liver, lungs and leukocytes. It also has a long half-like making it a potentially attractive drug for prophylaxis in liver transplantation (OLT).

We propose to administer a single (5mg/kg) dose of AmBisome ® following reperfusion of the new liver. Liver, subcutaneous fat, blood and bile samples will be analyzed for AMB levels 1-2 hours after drug administration. Blood and bile, and body fluid samples will be sequentially analyzed for 3 weeks post transplant. This will be done in 50 consecutive patients. The incidence of fungal infections and adverse effects will be monitored for three months.

Persistent AMB levels in blood bile and ascites, if found, will provide a good rationale for AmBisome ® prophylaxis for fungal infections in outpatients.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All adult liver transplant recipients receiving cadaveric liver transplants

排除标准

  • Patients with choledocho-jejunostomy reconstruction of the biliary tree.
  • Children less than 18 years of age
  • Patients with known allergy to Amphotericin B.

结局指标

主要结局

Tissue concentration of ambisome

时间窗: 3 months

Bile levels of amphotericin B over time (3 weeks)

时间窗: 3 weeks

Blood levels of amphotericin B over time (3 weeks)

时间窗: 3 weeks

次要结局

  • Rate of fungal infections(3 months)

研究者

研究点 (2)

Loading locations...

相似试验